Liege

• A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec … Ended recruitment
  2023-505617-24-00 4 2024-11-05 Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended recruitment
  2024-510753-10-00 5 2024-11-01 Prurigo Nodularis
• Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended recruitment
  2024-511202-23-00 4 2024-10-31 Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
• Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended recruitment
  2022-501457-37-00 5 2024-10-28 Myeloid Leukemia in Children with Down Syndrome
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru … Ended recruitment
  2022-502168-19-00 4 2024-10-22 chronic graft-versus-host disease
• A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended recruitment
  2024-510584-37-00 4 2024-10-22 Systemic Lupus Erythematosus
• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Ra … Ended recruitment
  2022-502269-13-00 4 2024-09-24 Glioma
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended recruitment
  2023-509716-29-00 9 2024-09-23 Solid Tumors, Colorectal Cancer and Breast Cancer
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive … Ended recruitment
  2024-510908-37-00 5 2024-08-28 KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
• Safety and preliminary efficacy of BNT314 in cancer patients with malignant solid tumors Ended recruitment
  2023-506053-38-00 1 2024-08-27 Advanced or metastatic malignant solid tumors
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa
• A study concerning the influence of tubal flushing with oil on pregnancy and live birth in women with fertility problems Ended recruitment
  2023-508896-35-00 6 2024-07-12 Infertile women with at least one patent tube at Hysterosalpingo-foam
• A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab … Ended recruitment
  2022-502954-15-00 4 2024-06-21 Idiopathic pulmonary fibrosis
• A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma Ended recruitment
  2022-502661-23-00 7 2024-06-11 Relapsed/refractory B-cell non-Hodgkin lymphoma
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended recruitment
  2023-509026-21-00 6 2024-06-03 severe asthma
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca … Ended recruitment
  2023-507995-33-00 9 2024-05-23 MSI-H/dMMR Gastric cancer
• Subcutaneous infliximab after a previous intravenous dose optimization (AMARETTO trial) Ended recruitment
  2023-508166-15-00 6 2024-04-29 Ulcerative colitis (UC), Inflammatory bowel disease type unclassified
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o … Ended recruitment
  2022-502518-98-00 5 2024-04-26 nonsegmental vitiligo
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended recruitment
  2023-505782-86-00 5 2024-04-23 Vitiligo
• A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended recruitment
  2023-507333-17-00 5 2024-04-15 HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Showing 337–360 of 639 trials